Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
Abstract Background Rivaroxaban could be an attractive alternative to low molecular weight heparin for the treatment of cancer‐associated venous thromboembolism (VTE) but the safety and effectiveness remain unclear. We examined risk of recurrent VTE and major bleeding associated with rivaroxaban tre...
Kaydedildi:
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wiley
2019-03-01
|
| Seri Bilgileri: | Cancer Medicine |
| Konular: | |
| Online Erişim: | https://doi.org/10.1002/cam4.1997 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|